• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To Medibank Private (ASX:MPL) Full-Year Profit and EPS Uplift

    Simply Wall St·08/20/2026 06:25:39
    語音播報
    • Medibank Private Limited has reported its full-year results for the period ended June 30, 2026, with net income of A$638.7 million, up from A$500.8 million a year earlier, and basic earnings per share from continuing operations rising to A$0.232 from A$0.182.
    • The step-up in profit and earnings per share points to improved operating performance across Medibank’s insurance and health services operations over the past year.
    • With this stronger full-year profit outcome, we’ll consider how the earnings uplift may influence Medibank Private’s existing investment narrative.

    Uncover the next big thing with 58 elite penny stocks that balance risk and reward.

    Medibank Private Investment Narrative Recap

    To own Medibank Private, you need to believe the Australian private health insurance market can still support steady membership and earnings, despite cost pressures and regulation. The latest jump in net income to A$638.7 million and higher EPS confirms a stronger operating year, but it does not remove the short term risk that premium increases and cost of living pressures could still drive policy downgrades and switching.

    The most directly relevant recent announcement is Medibank’s February 2026 interim dividend increase, with a fully franked A$0.083 per share payout equal to 76.8% of underlying NPAT and within the 75–85% target range. Together with the latest profit uplift, this reinforces Medibank’s existing capital management settings and highlights how earnings resilience supports returns to shareholders while the business continues to invest in digital and health services growth initiatives.

    Yet, investors should be aware of how rising hospital and healthcare provider costs could still pressure margins if...

    Read the full narrative on Medibank Private (it's free!)

    Medibank Private's narrative projects A$10.3 billion revenue and A$767.0 million earnings by 2029. This requires 5.4% yearly revenue growth and around A$303.6 million earnings increase from A$463.4 million today.

    Uncover how Medibank Private's forecasts yield a A$5.03 fair value, in line with its current price.

    Exploring Other Perspectives

    ASX:MPL 1-Year Stock Price Chart
    ASX:MPL 1-Year Stock Price Chart

    Four Simply Wall St Community fair value estimates for Medibank Private span roughly A$3.80 to A$7.14, showing how differently individual investors view the same earnings story. You can set these views against the risk that rising healthcare provider inflation may outpace premium growth, with important implications for Medibank’s profitability and pricing power over time.

    Explore 4 other fair value estimates on Medibank Private - why the stock might be worth as much as 42% more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Contemplating Other Strategies?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    • Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
    • The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
    • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.